StockTipsArenaBeta

BUY Emcure Pharmaceuticals Limited — BOB Capital Markets

BUYEmcure Pharmaceuticals Limited
Emcure Pharmaceuticals share price target & all analyst calls

byBOB Capital MarketsHorizon: NA (inferred 1 year)4 Nov 2026via Institutional / Brokerage Research

Entry₹2,160.4Inferred
Target₹2,544
Total upside +17.76%
Stop lossNot given
CMP₹2,212.81d ago
Active+2.43%+14.97%upside left 12 mo left
Follow BOB Capital Markets for new calls(61% target hit, 366 closed calls)Get alertsWatch EMCURE for new buy/sell callsGet alertsSee 7 other Long-term calls on EMCURESee 541 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:25 pm IST
19 supporting6 neutral2 opposing
Supports the BUY call (19)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·6 Nov · yesterday

3 other SEBI-registered advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · same horizon·5 Nov · 2d ago

Emcure Pharma shares hit 10% upper circuit as Q2 net profit rises

NewsHbl·4 Nov · 3d ago

(opens in new tab)

Emcure Pharma shares hit 10% upper circuit after FY27 guidance hike; Jefferies raises target price by 8%

NewsEt-Markets·4 Nov · 3d ago

(opens in new tab)

Emcure Pharma shares at record high! Stock soars 10% today, up 16% in 2 days: More rally ahead? Buy, sell or hold?

NewsLivemint·4 Nov · 3d ago

(opens in new tab)
Neutral / worth noting (6)

For approval of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026.

BSE · Board Meeting·3 Nov · 4d ago

(opens in new tab)

Emcure Pharmaceuticals has proposed a scheme of amalgamation for its wholly owned subsidiaries, Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, into the parent company.

BSE · Company Update·12 Oct · 4w ago

(opens in new tab)
Weighs against the BUY call (2)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Emcure Pharmaceuticals

All analyst calls on Emcure Pharmaceuticals

More from BOB Capital Markets

Every call and its outcome